코폴립 수반 만성 부비동염 시장 - 시장 인사이트, 역학, 시장 예측(2034년)

Key Highlights:

• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a clinically significant phenotype of chronic rhinosinusitis characterized by chronic sinonasal inflammation accompanied by benign bilateral inflammatory growths called nasal polyps.
• The Chronic Rhinosinusitis Phenotype with Nasal Polyps market is expected to grow steadily from 2025 to 2034, driven by rising awareness of inflammatory airway diseases, increased diagnosis rates, and the expanding use of biologic therapies. Regulatory approvals, improved treatment algorithms, and ongoing clinical research are expected to further strengthen the therapeutic landscape and support continued market expansion.
• DUPIXENT (dupilumab), developed by Regeneron and Sanofi, and NUCALA (mepolizumab), developed by GSK, are innovative biologic therapies approved for the treatment of chronic rhinosinusitis phenotype with nasal polyps. DUPIXENT works by blocking interleukin-4 and interleukin-13 signaling to reduce type 2 inflammation, while NUCALA targets interleukin-5 to decrease eosinophilic activity. These approvals represent a shift toward personalized, immune-targeted treatments for patients with chronic rhinosinusitis phenotype with nasal polyps.
• TEZSPIRE (tezepelumab) and depemokimab are two promising Phase III biologics advancing treatment for chronic rhinosinusitis with nasal polyps. Targeting TSLP and IL-5 respectively, both have demonstrated significant efficacy in reducing polyp burden and nasal symptoms. Their progress highlights a growing and innovative chronic rhinosinusitis phenotype with nasal polyps pipeline focused on long-acting, targeted therapies for patients with severe or treatment-resistant disease.
• In March 2025, the FDA has accepted GSK's Biologics License Application (BLA) for depemokimab as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps. The Prescription Drug User Fee Act (PDUFA) date is 16 December 2025.
• Market growth in chronic rhinosinusitis with nasal polyps is driven by advanced therapies and improved drug delivery technologies that better address chronic inflammation and symptom burden. While intranasal corticosteroids, antibiotics, and surgery remain standard treatments, high recurrence rates and limited long-term relief highlight the need for more durable solutions. New therapies aim to improve outcomes, reduce relapses, and enhance patient quality of life.

DelveInsight's comprehensive report titled "Chronic Rhinosinusitis Phenotype with Nasal Polyps - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of chronic rhinosinusitis phenotype with nasal polyps. The report presents historical and projected epidemiological data covering total prevalent cases, total diagnosed prevalent cases, gender-specific cases, age-specific cases, and treated cases of chronic rhinosinusitis phenotype with nasal polyps. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in Chronic Rhinosinusitis Phenotype with Nasal Polyps. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Overview

Chronic rhinosinusitis phenotype with nasal polyps is a well-defined clinical condition marked by ongoing inflammation of the nasal and sinus mucosa, identified through a combination of patient symptoms and objective diagnostic evidence. This condition is distinguished by the presence of benign, inflammatory polyps that develop within the sinonasal passages, most often on both sides. Although nasal polyps can also occur in diseases like cystic fibrosis or certain cancers, their occurrence in this context signifies a specific inflammatory form of chronic rhinosinusitis. These polyps are soft tissue growths that extend into the nasal cavity, usually arise bilaterally, and commonly originate from the ethmoid sinuses.

Individuals with chronic rhinosinusitis with nasal polyps often experience a range of persistent symptoms that impact daily functioning and quality of life. These include facial pain or pressure, nasal congestion, and a reduced or lost sense of smell. Many also report a runny nose, postnasal drip leading to throat irritation or soreness, and headaches. Discomfort may extend to the upper teeth, and symptoms like snoring are common due to nasal blockage.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Diagnosis and Treatment Algorithm

Diagnosis of chronic rhinosinusitis phenotype with nasal polyps requires objective confirmation using either a sinus CT scan or nasal endoscopy, which also helps differentiate between the polyp and non-polyp phenotypes. In adults, nasal polyps should be present in both nasal cavities to support a diagnosis of chronic rhinosinusitis phenotype with nasal polyps; the presence of a unilateral polyp warrants further evaluation to rule out other potential causes, including malignancy.

Management of chronic rhinosinusitis phenotype with nasal polyps involves a combination of medical and surgical interventions. First-line treatments include intranasal corticosteroids and saline irrigations to reduce inflammation and improve sinus drainage. Oral corticosteroids may be used short term for more severe symptoms but carry a risk of systemic side effects. Antibiotics are generally reserved for acute bacterial infections and offer limited benefit in reducing polyp size.

For patients who do not respond adequately to medical therapy, functional endoscopic sinus surgery (FESS) is considered to remove obstructive polyps and improve access for topical therapies. However, recurrence is common, especially in patients with comorbid asthma.

Recently approved biologics have transformed the treatment landscape. The US FDA has approved DUPIXENT, NUCALA, and XOLAIR as add-on maintenance therapies for chronic rhinosinusitis with nasal polyps in adults with inadequate response to corticosteroids. These targeted agents reduce polyp size, improve symptom control, and lower surgical needs by modulating underlying inflammatory pathways. Their approval marks a shift toward more personalized and durable disease management in chronic rhinosinusitis phenotype with nasal polyps.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Epidemiology

The epidemiology section of the chronic rhinosinusitis phenotype with nasal polyps market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of chronic rhinosinusitis phenotype with nasal polyps. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• As per secondary research, chronic rhinosinusitis with nasal polyps typically presents in middle age, with onset around 42 years and diagnosis between ages 40-60. While more common in males, females tend to experience more severe disease, including greater sinus involvement, higher corticosteroid use, and increased need for revision surgeries.
• According to secondary sources, chronic rhinosinusitis phenotype with nasal polyps affects approximately 1.1% of adults in the United States, whereas estimates in Europe range between 2.1% and 4.4%.
• The epidemiology of Chronic Rhinosinusitis Phenotype with Nasal Polyps is expected to change during the forecast period (2025-2034).

Chronic Rhinosinusitis Phenotype with Nasal Polyps Market Outlook

The chronic rhinosinusitis phenotype with nasal polyps therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Chronic Rhinosinusitis Phenotype with Nasal Polyps market in the 7MM is expected to change significantly during the forecast period 2025-2034.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Drug Chapters

Marketed Chronic Rhinosinusitis Phenotype with Nasal Polyps Drugs

DUPIXENT (dupilumab): Regeneron and Sanofi

DUPIXENT (dupilumab) is a fully-human monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that play a central role in type 2 inflammation. It is given as a subcutaneous injection every other week at different injection sites. DUPIXENT is the first FDA-approved medicine for adults with chronic rhinosinusitis with nasal polyposis, and the only approved therapy shown to shrink nasal polyp size and also improve the signs and symptoms of the associated chronic rhinosinusitis.

In June 2019, the US FDA approved DUPIXENT (dupilumab) for chronic rhinosinusitis with Nasal Polyposis.

In October 2019, the European Commission has granted approval of DUPIXENT (dupilumab) for the treatment of chronic rhinosinusitis with nasal polyposis.

NUCALA (mepolizumab): GSK

NUCALA (mepolizumab) is the first-in-class monoclonal antibody that targets IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils and maintaining them within normal levels.

In July 2021, US FDA has approved NUCALA (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps.

In November 2021, the European Commission has approved NUCALA (mepolizumab) as an add-on treatment for chronic rhinosinusitis with nasal polyps.

Emerging Chronic Rhinosinusitis Phenotype with Nasal Polyps Drugs

The Chronic Rhinosinusitis Phenotype with Nasal Polyps market is expected to evolve gradually, driven by the limited number of emerging therapies currently in development. Key players such as TEZSPIRE, by AstraZeneca/Amgen, and Depemokimab by GSK among others, are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex condition.

TEZSPIRE (tezepelumab): AstraZeneca/Amgen

TEZSPIRE (tezepelumab), developed by AstraZeneca and Amgen, is a first-in-class monoclonal antibody that inhibits thymic stromal lymphopoietin (TSLP), a key cytokine involved in initiating and sustaining airway and epithelial inflammation. TSLP is upregulated in conditions like severe asthma, chronic rhinosinusitis with nasal polyps, COPD, and eosinophilic esophagitis, where it correlates with disease severity. By blocking TSLP, Tezepelumab disrupts downstream inflammatory pathways, helping reduce exacerbations and improve disease control across multiple inflammatory disorders.

TEZSPIRE (tezepelumab) is currently being evaluated in a Phase III clinical trial (WAYPOINT) for the treatment of severe chronic rhinosinusitis with nasal polyps.

In March 2025, Positive findings from the Phase III WAYPOINT trial demonstrate that TEZSPIRE delivers a rapid and sustained therapeutic effect in patients with chronic rhinosinusitis with nasal polyps. The treatment led to significant reductions in nasal congestion and polyp size, while also substantially decreasing the need for surgical intervention.

Depemokimab/GSK3511294: GSK

Depemokimab, an IL-5-targeting monoclonal antibody, is the first ultra-long-acting biologic to enter Phase III trials for chronic rhinosinusitis with nasal polyps. Its prolonged half-life, strong binding affinity, and high potency support a twice-yearly dosing schedule, as evaluated in the ANCHOR trials. In these studies, depemokimab showed early and sustained suppression of blood eosinophils, a key indicator of IL-5-driven inflammation. Depemokimab is being evaluated in the Phase III ANCHOR-1 and ANCHOR-2 clinical trials for chronic rhinosinusitis with nasal polyps.

In March 2025, GSK reported positive results from the Phase III ANCHOR-1 and ANCHOR-2 trials evaluating depemokimab in adults with chronic rhinosinusitis with nasal polyps. Both trials met co-primary endpoints, showing significant improvements in nasal polyp size and obstruction with twice-yearly dosing versus placebo.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Market Segmentation

DelveInsight's 'Chronic Rhinosinusitis Phenotype with Nasal Polyps- Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future chronic rhinosinusitis phenotype with nasal polyps market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Market Size by Countries

The chronic rhinosinusitis phenotype with nasal polyps market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) chronic rhinosinusitis phenotype with nasal Polyps market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Drugs Uptake

This section focuses on the sales uptake of potential chronic rhinosinusitis phenotype with nasal polyps drugs that have recently been launched or are anticipated to be launched in the chronic rhinosinusitis phenotype with nasal polyps market between 2020 and 2034. It estimates the market penetration of chronic rhinosinusitis phenotype with nasal polyps drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the chronic rhinosinusitis phenotype with nasal polyps market.

The emerging chronic rhinosinusitis phenotype with nasal polyps therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry, and other market dynamics, and the unmet need they fulfill in the chronic rhinosinusitis phenotype with nasal polyps market.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Market Access and Reimbursement

DelveInsight's 'Chronic Rhinosinusitis Phenotype with Nasal Polyps- Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of chronic rhinosinusitis phenotype with nasal polyps.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current chronic rhinosinusitis phenotype with nasal polyps market trends and fill gaps in secondary findings, we interview KOLs and SMEs working in the chronic rhinosinusitis phenotype with nasal polyps domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or chronic rhinosinusitis phenotype with nasal polyps market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Chronic Rhinosinusitis Phenotype with Nasal Polyps unmet needs.

Chronic Rhinosinusitis Phenotype with Nasal Polyps: KOL Insights

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Stanford University School of Medicine, US, University Hospital Marburg, Germany, University of Barcelona, Spain, Universite Paris-Saclay, France, Cambridge University, UK, and Toho University Ohashi Medical Center, Japan, among others.

"At present, there is no validated biomarker that can definitively differentiate chronic rhinosinusitis with nasal polyps from chronic rhinosinusitis without nasal polyps, acute sinusitis, or the absence of sinus disease. Although eosinophil-related markers such as eosinophilic cationic protein, interleukin-5, and eotaxin may aid in identifying chronic rhinosinusitis with nasal polyps, not all patients exhibit elevated type 2 inflammatory markers."

"Biologic therapies are increasingly being explored as treatment options for patients with Chronic Rhinosinusitis Phenotype with Nasal Polyps who do not respond adequately to intranasal corticosteroids. They are particularly considered for individuals who are not suitable candidates for surgery, have experienced recurrence or are at high risk of recurrence after nasal polyp surgery, or have coexisting type 2 inflammatory conditions like asthma."

"The connection between asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) is well recognized. Most individuals with asthma exhibit signs of sinonasal inflammation, and CRSwNP commonly coexists with asthma. Likewise, many patients diagnosed with CRSwNP also have underlying asthma, highlighting the overlap between these two inflammatory airway diseases."

Competitive Intelligence Analysis

We conduct a competitive and market intelligence analysis of the chronic rhinosinusitis phenotype with nasal polyps market, utilizing various competitive intelligence tools such as SWOT analysis and market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for the chronic rhinosinusitis phenotype with nasal polyps. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, patent details, and other information for emerging chronic rhinosinusitis phenotype with nasal polyps therapies.

Chronic Rhinosinusitis Phenotype with Nasal Polyps Report Insights

• Chronic Rhinosinusitis Phenotype with Nasal Polyps Patient Population Therapeutic Approaches
• Chronic Rhinosinusitis Phenotype with Nasal Polyps Pipeline Analysis
• Chronic Rhinosinusitis Phenotype with Nasal Polyps Market Size and Trends
• Chronic Rhinosinusitis Phenotype with Nasal Polyps Market Opportunities
• Impact of Upcoming Therapies

Chronic Rhinosinusitis Phenotype with Nasal Polyps Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Chronic Rhinosinusitis Phenotype with Nasal Polyps Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Chronic Rhinosinusitis Phenotype with Nasal Polyps Market
• Chronic Rhinosinusitis Phenotype with Nasal Polyps Drugs Uptake

Chronic Rhinosinusitis Phenotype with Nasal Polyps Report Assessment

• Chronic Rhinosinusitis Phenotype with Nasal Polyps Current Treatment Practices
• Unmet Needs
• Chronic Rhinosinusitis Phenotype with Nasal Polyps Pipeline Product Profiles
• Chronic Rhinosinusitis Phenotype with Nasal Polyps Market Attractiveness

Key Questions:

• How common is chronic rhinosinusitis phenotype with nasal polyps?
• What are the key findings of chronic rhinosinusitis phenotype with nasal polyps epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for chronic rhinosinusitis phenotype with nasal polyps?
• What are the disease risk, burden, and unmet needs of chronic rhinosinusitis phenotype with nasal polyps?
• At what CAGR is the chronic rhinosinusitis phenotype with nasal polyps market and its epidemiology expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the chronic rhinosinusitis phenotype with nasal polyps market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of chronic rhinosinusitis phenotype with nasal polyps in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of chronic rhinosinusitis phenotype with nasal polyps?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the chronic rhinosinusitis phenotype with nasal polyps market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for Chronic Rhinosinusitis Phenotype with Nasal Polyps?

The main goals in managing chronic rhinosinusitis phenotype with nasal polyps are to control inflammation, restore sinus drainage, and improve mucociliary function. Treatment focuses on relieving symptoms like nasal congestion, facial pressure, loss of smell, and discharge, while enhancing quality of life, reducing flare-ups, and minimizing the need for systemic therapy or surgery.

2. What are the challenges in managing Chronic Rhinosinusitis Phenotype with Nasal Polyps?

Management of Chronic Rhinosinusitis Phenotype with Nasal Polyps is complex due to its chronic inflammatory nature, high recurrence rates, and heterogeneity in patient response. Identifying the underlying inflammatory endotype is essential for guiding targeted therapy, yet remains clinically challenging. Coexisting conditions like asthma or aspirin-exacerbated respiratory disease further complicate treatment. Limited biomarker availability, variable response to corticosteroids, restricted access to biologics, and the need for repeated surgeries contribute to the difficulty in achieving long-term disease control.

3. What are the key factors driving the growth of the Chronic Rhinosinusitis Phenotype with Nasal Polyps market?

The growth of the Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) market is driven by increasing clinical recognition of the disease, a rise in associated comorbid conditions such as asthma and allergic rhinitis, and expanding therapeutic innovation. The approval and adoption of targeted biologics and sustained-release drug-eluting implants have provided effective options for patients with severe or refractory disease. Additionally, advancements in diagnostic imaging and endotyping, improved healthcare access, growing emphasis on patient-reported outcomes, and evolving reimbursement policies are further accelerating market expansion.

4. How will the Chronic Rhinosinusitis Phenotype with Nasal Polyps Market and Epidemiology Forecast Report benefit the clients?

The report will provide comprehensive insights into the current Chronic Rhinosinusitis Phenotype with Nasal Polyps market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.

Table of Contents

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

3.1.. Market Share (%) Distribution by Therapies in 2024

3.2.. Market Share (%) Distribution by Therapies in 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

7.1.. Introduction

• 7.2. Types

7.3.. Causes

7.4.. Pathophysiology

7.5.. Symptoms

7.6.. Risk Factor

7.7.. Diagnosis

7.7.1.. Diagnostic Algorithm

7.7.2.. Diagnostic Guidelines

7.8.. Treatment and Management

7.8.1.. Treatment Algorithm

7.8.2.. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
• 8.3. Total Prevalent Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps in the 7MM
• 8.4. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps in the 7MM
• 8.5. The US
  • 8.5.1. Total Prevalent Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.5.2. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.5.3. Gender-specific Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.5.4. Age-specific Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.5.5. Treated Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
• 8.6. EU4 and the UK
  • 8.6.1. Total Prevalent Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.6.2. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.6.3. Gender-specific Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.6.4. Age-specific Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.6.5. Treated Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
• 8.7. Japan
  • 8.7.1. Total Prevalent Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.7.2. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.7.3. Gender-specific Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.7.4. Age-specific Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 8.7.5. Treated Cases of Chronic Rhinosinusitis Phenotype with Nasal Polyps

9. Patient Journey

10. Marketed Therapies

• 10.1. Key Cross Competition
• 10.2. DUPIXENT (dupilumab): Regeneron and Sanofi
  • 10.2.1. Drug Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
• 10.3. NUCALA (mepolizumab): GSK
  • 10.3.1. Drug Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Development Activities
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. TEZSPIRE (tezepelumab): AstraZeneca/Amgen
  • 11.2.1. Drug Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analysts' Views
• 11.3. Depemokimab/GSK3511294: GSK
  • 11.3.1. Drug Description
  • 11.3.2. Other Development Activities
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analysts' Views

12. Chronic Rhinosinusitis Phenotype with Nasal Polyps: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
  • 12.2.1. Cost Assumptions and Rebates
  • 12.2.2. Pricing Trends
  • 12.2.3. Analogue Assessment
  • 12.2.4. Launch Year and Therapy Uptake
• 12.3. Market Outlook
• 12.4. Attribute Analysis
• 12.5. Total Market Size of Chronic Rhinosinusitis Phenotype with Nasal Polyps in the 7MM
• 12.6. Market Size of Chronic Rhinosinusitis Phenotype with Nasal Polyps by Therapies in the 7MM
• 12.7. The US Market Size
  • 12.7.1. Total Market Size of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 12.7.2. Market Size of Chronic Rhinosinusitis Phenotype with Nasal Polyps by Therapies
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Total Market Size of Chronic Rhinosinusitis Phenotype with Nasal Polyps
  • 12.8.2. Market Size of Chronic Rhinosinusitis Phenotype with Nasal Polyps by Therapies

12.9.. Japan Market Size

• 12.9.1. Total Market Size of Chronic Rhinosinusitis Phenotype with Nasal Polyps
• 12.9.2. Market Size of Chronic Rhinosinusitis Phenotype with Nasal Polyps by Therapies

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Chronic Rhinosinusitis Phenotype with Nasal Polyps Market Access and Reimbursement

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Abbreviations and Acronyms
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight